Reuters 
(3/28, Kelly) reports that, according to a study
presented at the American College of Cardiology meeting and published
online in the Journal of the American Medical Association, individuals
with symptoms of heart attack who were given a treatment containing
glucose, insulin and potassium by paramedics were less likely to
experience cardiac arrest, compared to patients who did not receive the
treatment,
although the treatment may not prevent patients from progressing to a
heart attack.
(3/28, Kelly) reports that, according to a study
presented at the American College of Cardiology meeting and published
online in the Journal of the American Medical Association, individuals
with symptoms of heart attack who were given a treatment containing
glucose, insulin and potassium by paramedics were less likely to
experience cardiac arrest, compared to patients who did not receive the
treatment,
although the treatment may not prevent patients from progressing to a
heart attack.
HealthDay
(3/28, Mann) reports, "In the trial, paramedics from 13 cities were
trained to administer the solution after determining that an individual
was likely having or about to have a heart attack." Individuals "who
received the solution immediately after being diagnosed with acute
coronary syndrome...were 50 percent less likely to experience cardiac
arrest or die compared to those who received the placebo." The findings
"were even more pronounced for people with more severe ST-elevation
heart attacks."
(3/28, Mann) reports, "In the trial, paramedics from 13 cities were
trained to administer the solution after determining that an individual
was likely having or about to have a heart attack." Individuals "who
received the solution immediately after being diagnosed with acute
coronary syndrome...were 50 percent less likely to experience cardiac
arrest or die compared to those who received the placebo." The findings
"were even more pronounced for people with more severe ST-elevation
heart attacks."
MedPage Today
(3/28, Neale) reports, however, that the treatment "did not reduce
progression to MI." The investigators found that "within 24 hours of
symptom onset, 48.7% of those who received the infusion and 52.6% of
those who received placebo progressed to MI (P=0.28)." Additionally,
"there was no difference between the groups in 30-day mortality
(P=0.27)."
(3/28, Neale) reports, however, that the treatment "did not reduce
progression to MI." The investigators found that "within 24 hours of
symptom onset, 48.7% of those who received the infusion and 52.6% of
those who received placebo progressed to MI (P=0.28)." Additionally,
"there was no difference between the groups in 30-day mortality
(P=0.27)."
HeartWire
(3/28, O'Riordan) reports, "Still, despite the negative primary end
point, investigators, led by Dr Harry Selker (Tufts Medical Center,
Boston, MA), are pleased with the results, believing that after years of
futile study, they have finally found some clinical evidence to support
the experimental data suggesting that GIK [glucose-insulin-potassium]
myocardial metabolic support could protect the heart in the ACS
setting."
(3/28, O'Riordan) reports, "Still, despite the negative primary end
point, investigators, led by Dr Harry Selker (Tufts Medical Center,
Boston, MA), are pleased with the results, believing that after years of
futile study, they have finally found some clinical evidence to support
the experimental data suggesting that GIK [glucose-insulin-potassium]
myocardial metabolic support could protect the heart in the ACS
setting."
No comments:
Post a Comment